Capital International’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$34.5M Buy
591,781
+11,980
+2% +$707K 1.11% 23
2026
Q2
$32.5M Buy
579,801
+9,224
+2% +$480K 1.06% 27
2026
Q1
$27.4M Buy
570,577
+268,954
+89% +$11.8M 1.01% 26
2025
Q4
$11.7M Buy
301,623
+97,251
+48% +$3.71M 0.41% 64
2025
Q3
$7.21M Buy
204,372
+4,558
+2% +$165K 0.26% 89
2025
Q2
$7.2M Buy
+199,814
New +$6.62M 0.28% 88

Other funds holding RPRX

Capital International's RPRX Position: Q3 2026 in Review

Capital International increased its Royalty Pharma (RPRX) stake by 2.1% in Q3 2026, buying an estimated $707K and bringing the position to 591,781 shares worth $34.5M. The position accounts for 1.11% of the portfolio, ranked #23.

Capital International first reported a position in RPRX in Q2 2025 and has held it in 6 quarters since. 593 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Capital International held 591,781 shares of Royalty Pharma worth $34.5M as of Q3 2026.
  • Capital International bought 11,980 Royalty Pharma shares in Q3 2026, an estimated $707K.
  • Royalty Pharma made up 1.11% of Capital International's portfolio in Q3 2026, its #23 holding.
  • Capital International first reported a position in Royalty Pharma in Q2 2025 and has held it in 6 quarters since.
  • 593 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Capital International's 13F filing for Q3 2026, filed 12 Nov 2026.